SDGR
Schrödinger, Inc.
Healthcare · Medical - Healthcare Information Services
Deeply Undervalued·Quality 75·RSI 43·DCF -516%·Conviction 80
Investment Thesis — Schrödinger, Inc.
The market is capitulating on Schrödinger after repeated execution missteps, extrapolating recent pipeline delays and cash burn as structural flaws. This ignores the growing strategic value of their platform as AI-driven drug discovery becomes a necessity for pharma, not a luxury, and underestimates the embedded optionality from their partnerships.
Catalysts
- Major pharma partnership milestone or licensing deal
- Evidence of accelerating platform adoption in quarterly results
- Strategic interest from a large pharma or tech acquirer
Risk Factors
- Failure to convert partnerships into meaningful revenue
- Continued cash burn leading to dilutive capital raise
- Loss of key talent or competitive leapfrogging by rivals
Key Debates
Fwd Rev Growth turns positive by Q1 2025, negating -80% estimate.
Net Margin turns positive by H2 2025 as operating expenses decline.
Short squeeze pushes SDGR above $18.50 by Q4 2024.